Insider · CIK 0001619444
Larry Douglas Altstiel
Files at PMN (ProMIS Neurosciences Inc.). First filing -, latest -.
In brief
Larry Douglas Altstiel files SEC Form 4 as officer at PMN (ProMIS Neurosciences Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Larry Douglas Altstiel has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2025 | PMN ProMIS Neurosciences Inc. | AGrant or award Option (right to buy)derivative | +165,000 | $0.00 | $0 | 165,000 | Sep 24, 2025 |
| Nov 18, 2024 | PMN ProMIS Neurosciences Inc. | AGrant or award Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Nov 20, 2024 |
| Oct 26, 2023 | PMN ProMIS Neurosciences Inc. | AGrant or award Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Oct 30, 2023 |
Questions about Larry Douglas Altstiel
Answered from the filings on this page, as of the latest one.
Is Larry Douglas Altstiel buying or selling?
Larry Douglas Altstiel has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Larry Douglas Altstiel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Larry Douglas Altstiel has 0.
Where does Larry Douglas Altstiel file Form 4?
Larry Douglas Altstiel has filed Form 4 at PMN (ProMIS Neurosciences Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.